HUP0400807A2 - EP4 receptor szelektív agonisták csontritkulás kezelésében - Google Patents
EP4 receptor szelektív agonisták csontritkulás kezelésébenInfo
- Publication number
- HUP0400807A2 HUP0400807A2 HU0400807A HUP0400807A HUP0400807A2 HU P0400807 A2 HUP0400807 A2 HU P0400807A2 HU 0400807 A HU0400807 A HU 0400807A HU P0400807 A HUP0400807 A HU P0400807A HU P0400807 A2 HUP0400807 A2 HU P0400807A2
- Authority
- HU
- Hungary
- Prior art keywords
- heteroatoms
- compounds
- bone
- treatment
- group
- Prior art date
Links
- 208000001132 Osteoporosis Diseases 0.000 title abstract 2
- 101150109738 Ptger4 gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 206010065687 Bone loss Diseases 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- 208000002679 Alveolar Bone Loss Diseases 0.000 abstract 1
- 208000010392 Bone Fractures Diseases 0.000 abstract 1
- 206010051728 Bone erosion Diseases 0.000 abstract 1
- 206010017076 Fracture Diseases 0.000 abstract 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 201000001245 periodontitis Diseases 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány (I) általános képletű vegyületekre, a képletben aszaggatott vonal jelentése egy adott esetben jelen levővegyértékkötés; X jelentése -CH2- csoport vagy O; Z jelentése -(CH2)3-, tienil-, tiazolil- vagy fenilcsoport; Q jelentése karboxil-,(1-4 szénatomos alkoxi)karbonil- vagy tetrazolilcsoport; R2 jelentése-Ar vagy -Ar1-V-Ar2 általános képletű csoport; V jelentésevegyértékkötés, -O-, -OCH2- vagy -CH2O- csoport; Ar jelentése adottesetben helyettesített 5-8 tagú gyűrű, amely adott esetben 1-4heteroatomot tartalmaz, vagy egy biciklusos gyűrű, amely kétkondenzált 5-6 tagú gyűrűből áll, amelyek 1-4 heteroatomottartalmaznak; és Ar1 és Ar2 jelentése adott esetben helyettesített 5-8tagú gyűrű, amely adott esetben 1-4 heteroatomot tartalmaz; avegyületeket tartalmazó gyógyászati készítményekre vonatkozik. Atalálmány tárgya továbbá a vegyületek alkalmazása alacsonycsonttömeggel jellemezhető állapotok, különösen csontritkulás, törés,csontritkulásos törés, csonthiány, gyermekkori idiopátiáscsontvesztés, alveoláris csontvesztés, mandibuláris csontvesztés,csontkivésés, periodontitisszel vagy protetikus benövéssel járócsontvesztés kezelésére alkalmas gyógyszerkészítmények előállítására. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25327500P | 2000-11-27 | 2000-11-27 | |
PCT/IB2001/002073 WO2002042268A2 (en) | 2000-11-27 | 2001-11-05 | Ep4 receptor selective agonists in the treatment of osteoporosis |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0400807A2 true HUP0400807A2 (hu) | 2004-07-28 |
Family
ID=22959588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0400807A HUP0400807A2 (hu) | 2000-11-27 | 2001-11-05 | EP4 receptor szelektív agonisták csontritkulás kezelésében |
Country Status (41)
Country | Link |
---|---|
US (3) | US6552067B2 (hu) |
EP (1) | EP1339678B1 (hu) |
JP (2) | JP3984164B2 (hu) |
KR (1) | KR20030053063A (hu) |
CN (1) | CN1476429A (hu) |
AR (1) | AR035074A1 (hu) |
AT (1) | ATE374182T1 (hu) |
AU (1) | AU2002210848A1 (hu) |
BG (1) | BG107697A (hu) |
BR (1) | BR0115687A (hu) |
CA (1) | CA2429850C (hu) |
CY (1) | CY1106976T1 (hu) |
CZ (1) | CZ20031257A3 (hu) |
DE (1) | DE60130675T2 (hu) |
DK (1) | DK1339678T3 (hu) |
EA (1) | EA200300379A1 (hu) |
EC (1) | ECSP034623A (hu) |
EE (1) | EE200300246A (hu) |
ES (1) | ES2291361T3 (hu) |
GT (2) | GT200100238A (hu) |
HN (1) | HN2001000266A (hu) |
HU (1) | HUP0400807A2 (hu) |
IL (1) | IL155368A0 (hu) |
IS (1) | IS6775A (hu) |
MA (1) | MA26961A1 (hu) |
MX (1) | MXPA03004623A (hu) |
NO (1) | NO20032360L (hu) |
NZ (1) | NZ525164A (hu) |
OA (1) | OA12533A (hu) |
PA (1) | PA8533901A1 (hu) |
PE (1) | PE20020637A1 (hu) |
PL (1) | PL362030A1 (hu) |
PT (1) | PT1339678E (hu) |
SI (1) | SI1339678T1 (hu) |
SK (1) | SK5562003A3 (hu) |
SV (1) | SV2003000746A (hu) |
TN (1) | TNSN01166A1 (hu) |
TW (1) | TW200424170A (hu) |
UY (1) | UY27038A1 (hu) |
WO (1) | WO2002042268A2 (hu) |
ZA (1) | ZA200302803B (hu) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ525164A (en) * | 2000-11-27 | 2005-04-29 | Pfizer Prod Inc | EP4 receptor selective agonists in the treatment of osteoporosis |
RU2288913C2 (ru) | 2001-07-16 | 2006-12-10 | Ф.Хоффманн-Ля Рош Аг | Аналоги простагландинов, способ их получения и фармацевтическая композиция, обладающая селективной агонистической активностью в отношении рецептора ep4 |
AU2002328338C1 (en) | 2001-07-16 | 2009-01-08 | Ono Pharmaceutical Co., Ltd | 2 pyrrolidone derivatives as prostanoid agonists |
MXPA04000757A (es) * | 2001-07-23 | 2004-07-08 | Ono Pharmaceutical Co | Remedios para enfermedades con perdida de masa de hueso que tienen agonistas ep4 como ingrediente activo. |
US20040254230A1 (en) * | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
MXPA04008596A (es) | 2002-03-05 | 2004-12-06 | Ono Pharmaceutical Co | Compuestos derivados de 8-azaprostaglandina y farmacos que contienen los compuestos como ingrediente activo. |
EP1487437B1 (en) * | 2002-03-18 | 2006-08-16 | Pfizer Products Inc. | Use of selective ep4 receptor agonists for the treatment of diseases |
MXPA04009036A (es) * | 2002-03-18 | 2005-01-25 | Pfizer Prod Inc | Uso de agonistas del receptor ep4 selectivos para el tratamiento de la insuficiencia hepatica, perdida de permeabilidad del ductus arterioso, glaucoma o hipertension ocular. |
US6573294B1 (en) | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
WO2003103664A1 (en) * | 2002-06-06 | 2003-12-18 | Merck Frosst Canada & Co. | 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases |
WO2003103772A1 (en) | 2002-06-06 | 2003-12-18 | Merck Frosst Canada & Co. | 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma |
EP1556347A4 (en) * | 2002-06-10 | 2006-08-09 | Applied Research Systems | GAMMA LACTAME AS PROSTAGLAND INAGONISTS AND THEIR USE |
GB0219143D0 (en) * | 2002-08-16 | 2002-09-25 | Univ Leicester | Modified tailed oligonucleotides |
ES2393321T3 (es) | 2002-10-10 | 2012-12-20 | Ono Pharmaceutical Co., Ltd. | Promotores de la producción de factores de reparación endógenos |
AU2003275838A1 (en) * | 2002-10-25 | 2004-05-13 | Beunard, Jean-Luc | Pyrrolidin-2-on derivatives as ep4 receptor agonists |
US7196082B2 (en) | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
WO2004043354A2 (en) | 2002-11-08 | 2004-05-27 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
US7053085B2 (en) * | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
CA2511255C (en) * | 2003-01-10 | 2009-04-07 | F. Hoffmann-La Roche Ag | 2-piperidone derivatives as prostaglandin agonists |
JP4582456B2 (ja) * | 2003-01-21 | 2010-11-17 | 小野薬品工業株式会社 | 8−アザプロスタグランジン誘導体およびその医薬用途 |
JP4662926B2 (ja) | 2003-03-03 | 2011-03-30 | メルク セローノ ソシエテ アノニム | プロスタグランジン作動薬としてのγ−ラクタム誘導体 |
US6734206B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
US6734201B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
WO2005012232A2 (en) | 2003-07-18 | 2005-02-10 | Applied Research Systems Ars Holding N.V. | Hydrazide derivatives as prostaglandin receptors modulators |
US7034051B2 (en) * | 2003-08-28 | 2006-04-25 | Adolor Corporation | Fused bicyclic carboxamide derivatives and methods of their use |
US7576122B2 (en) | 2003-09-02 | 2009-08-18 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
KR20060090801A (ko) | 2003-09-04 | 2006-08-16 | 머크 앤드 캄파니 인코포레이티드 | 고안압증 치료용 안용 조성물 |
JP2007504236A (ja) | 2003-09-04 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼用組成物 |
WO2005027931A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist |
BRPI0417621A (pt) * | 2003-12-17 | 2007-04-10 | Pfizer Prod Inc | terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea |
US7169807B2 (en) * | 2004-04-09 | 2007-01-30 | Allergan, Inc. | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists |
JP2008507521A (ja) | 2004-07-20 | 2008-03-13 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼科用組成物 |
JP4893999B2 (ja) * | 2004-10-22 | 2012-03-07 | 小野薬品工業株式会社 | 吸入用医薬組成物 |
US20080132543A1 (en) * | 2004-10-26 | 2008-06-05 | Wha Bin Im | Therapeutic and Delivery Methods of Prostaglandin Ep4, Agonists |
WO2006052630A1 (en) * | 2004-11-04 | 2006-05-18 | Allergan, Inc. | Therapeutic substituted piperidone compounds |
CA2586752A1 (en) * | 2004-11-08 | 2006-05-18 | Allergan, Inc. | Substituted pyrrolidone compounds as ep4 agonists |
US7101906B2 (en) * | 2004-11-16 | 2006-09-05 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
US7183324B2 (en) | 2004-11-23 | 2007-02-27 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
KR100890490B1 (ko) * | 2005-01-27 | 2009-03-26 | 아사히 가세이 파마 가부시키가이샤 | 헤테로 6원환 화합물 및 그의 용도 |
US7531533B2 (en) | 2005-01-27 | 2009-05-12 | Asahi Kasei Pharma Corporation | 6-Membered heterocyclic compound and use thereof |
WO2006121708A1 (en) * | 2005-05-06 | 2006-11-16 | Allergan, Inc. | Substituted beta-lactams and their use in medicine |
US7772392B2 (en) | 2005-05-06 | 2010-08-10 | Allergan, Inc. | Therapeutic substituted β-lactams |
US7893107B2 (en) * | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
KR100598678B1 (ko) * | 2006-02-15 | 2006-07-19 | (주)아이앤씨 | 수직형 대형 폐기물 파쇄기 |
US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
EP2094839B1 (en) | 2006-12-08 | 2020-02-05 | University of Rochester | Expansion of hematopoietic stem cells |
BRPI0721067A2 (pt) * | 2006-12-18 | 2014-02-25 | Allergan Inc | Métodos e composições para tratar distúrbios gastrointestinais. |
KR20100016299A (ko) | 2007-05-08 | 2010-02-12 | 고쿠리츠다이가쿠호진 하마마츠이카다이가쿠 | Ep4 아고니스트를 함유하여 이루어지는 세포 상해성 t 세포의 활성화제 |
WO2008144623A1 (en) * | 2007-05-23 | 2008-11-27 | Allergan, Inc. | Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure |
US8063033B2 (en) * | 2008-01-18 | 2011-11-22 | Allergan, Inc. | Therapeutic beta-lactams |
US8202855B2 (en) | 2008-03-04 | 2012-06-19 | Allergan, Inc | Substituted beta-lactams |
US7705001B2 (en) * | 2008-03-18 | 2010-04-27 | Allergan, Inc | Therapeutic substituted gamma lactams |
EP2320906B1 (en) * | 2008-08-14 | 2016-02-24 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as ep4 receptor antagonists |
WO2010116270A1 (en) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | Ep2/4 agonists |
US20120190637A1 (en) | 2009-10-14 | 2012-07-26 | Gemmus Pharma, Inc. | Combination therapy treatment for viral infections |
ES2593229T3 (es) * | 2010-03-08 | 2016-12-07 | Kaken Pharmaceutical Co., Ltd. | Nuevo agonista de EP4 |
CA2738045C (en) | 2010-05-28 | 2019-02-19 | Simon Fraser University | Conjugate compounds, methods of making same, and uses thereof |
EP2397141A1 (en) * | 2010-06-16 | 2011-12-21 | LEK Pharmaceuticals d.d. | Process for the synthesis of beta-amino acids and derivatives thereof |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
EP2675491A2 (en) | 2011-02-17 | 2013-12-25 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013105997A2 (en) | 2011-02-23 | 2013-07-18 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013123272A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
EP2814526B1 (en) | 2012-02-16 | 2016-11-02 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
EP2814527A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
WO2013123270A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
KR102151578B1 (ko) * | 2012-07-19 | 2020-09-03 | 카이맨 케미칼 컴파니 인코포레이티드 | Ep4-매개의 골 관련 질병 및 질환을 위한 디플루오로락탐 조성물 |
JP6400479B2 (ja) | 2012-10-29 | 2018-10-03 | 株式会社カルディオ | 肺疾患特異的治療剤 |
JP6368351B2 (ja) | 2013-03-15 | 2018-08-01 | ケイマン ケミカル カンパニー, インコーポレーテッド | ジフルオロラクタムアナログを合成する方法 |
CA2906134A1 (en) | 2013-03-15 | 2014-09-18 | Cayman Chemical Company, Inc. | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
US9676712B2 (en) | 2013-03-15 | 2017-06-13 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
JP2016527006A (ja) | 2013-07-19 | 2016-09-08 | ケイマン ケミカル カンパニー, インコーポレーテッド | 骨成長を促進するための方法、システム、及び組成物 |
NZ717739A (en) | 2013-08-09 | 2023-12-22 | Ardelyx Inc | Compounds and methods for inhibiting phosphate transport |
WO2015056504A1 (ja) | 2013-10-15 | 2015-04-23 | 小野薬品工業株式会社 | 薬剤溶出性ステントグラフト |
US9650414B1 (en) | 2014-05-30 | 2017-05-16 | Simon Fraser University | Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof |
BR112016028614A8 (pt) | 2014-06-06 | 2021-04-06 | Allergan Inc | novos agonistas de ep4, composição farmacêutica compreendendo os mesmos e seu uso |
US9540357B1 (en) | 2014-07-31 | 2017-01-10 | Allergan, Inc. | 15-aryl prostaglandins as EP4 agonists, and methods of use thereof |
EP3307747A4 (en) | 2015-06-12 | 2019-02-27 | Simon Fraser University | AMIDE-LINKED EP4-BISPHOSPHONATE AGONIST COMPOUNDS AND USES THEREOF |
CN107011377B (zh) * | 2017-05-03 | 2019-02-26 | 南通书创药业科技有限公司 | 一种β-羰基磷酸酯的制备方法 |
BR112020012405A2 (pt) | 2017-12-25 | 2020-11-24 | Asahi Kasei Pharma Corporation | composto cíclico de 6 membros contendo nitrogênio. |
US20200368223A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Methods for inhibiting phosphate transport |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1158163A (en) | 1966-06-15 | 1969-07-16 | Berk Ltd | Improvements in or relating to Polymer Compositions |
ZA72645B (en) * | 1971-03-05 | 1972-11-29 | Upjohn Co | Prostaglandin analogs |
DE2346706A1 (de) * | 1973-09-17 | 1975-04-03 | Hoechst Ag | Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung |
US3975399A (en) | 1974-08-06 | 1976-08-17 | E. I. Du Pont De Nemours And Company | 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones |
US4113873A (en) | 1975-04-26 | 1978-09-12 | Tanabe Seiyaku Co. Ltd. | 8-azaprostanoic acid derivatives |
NL7604330A (nl) | 1975-04-28 | 1976-11-01 | Syntex Inc | Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten. |
DE2528664A1 (de) | 1975-06-27 | 1977-01-13 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
IL49325A (en) | 1976-03-31 | 1979-11-30 | Labaz | 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them |
DE2619638A1 (de) | 1976-05-04 | 1977-11-17 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
US4177346A (en) * | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
CA1077948A (en) * | 1976-08-06 | 1980-05-20 | Albin J. Nelson | 1,-5 disubstituted-2-pyrrolidones and processes for their production |
US4320136A (en) | 1980-08-11 | 1982-03-16 | E. I. Du Pont De Nemours And Company | 8-Aza-16,16-difluoroprostanoids |
US4456613A (en) | 1982-12-27 | 1984-06-26 | E. I. Du Pont De Nemours And Company | 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof |
TW288010B (hu) | 1992-03-05 | 1996-10-11 | Pfizer | |
SE9302334D0 (sv) | 1993-07-06 | 1993-07-06 | Ab Astra | New compounds |
ZA944647B (en) | 1993-07-06 | 1995-01-06 | Astra Ab | Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives |
US5955481A (en) | 1994-03-28 | 1999-09-21 | Nissan Chemical Industries, Ltd. | Pyridine type thiazolidines |
TW420669B (en) | 1994-03-28 | 2001-02-01 | Nissan Chemical Ind Ltd | Pyridine type thiazolidines |
US5703108A (en) * | 1996-02-28 | 1997-12-30 | Pfizer Inc. | Bone deposition by certain prostaglandin agonists |
WO2000021532A1 (en) | 1998-10-15 | 2000-04-20 | Merck & Co., Inc. | Methods for inhibiting bone resorption |
JP2002527400A (ja) * | 1998-10-15 | 2002-08-27 | メルク エンド カムパニー インコーポレーテッド | 骨形成刺激方法 |
TR200201643T2 (tr) * | 1999-12-22 | 2002-11-21 | Pfizer Products Inc. | Osteoporoz tedavisi için EP4 reseptörünü seçici agonistler. |
DE60120007T2 (de) * | 2000-01-31 | 2006-11-16 | Pfizer Products Inc., Groton | Verwendung von Aktivatoren des Prostaglandinrezeptores 4 zur Behandlung von akuter oder chronischer Niereninsuffizienz |
US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
NZ525164A (en) * | 2000-11-27 | 2005-04-29 | Pfizer Prod Inc | EP4 receptor selective agonists in the treatment of osteoporosis |
US6573294B1 (en) * | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
-
2001
- 2001-11-05 NZ NZ525164A patent/NZ525164A/en unknown
- 2001-11-05 AU AU2002210848A patent/AU2002210848A1/en not_active Abandoned
- 2001-11-05 BR BR0115687-0A patent/BR0115687A/pt not_active Withdrawn
- 2001-11-05 SK SK556-2003A patent/SK5562003A3/sk not_active Application Discontinuation
- 2001-11-05 HU HU0400807A patent/HUP0400807A2/hu unknown
- 2001-11-05 ES ES01978757T patent/ES2291361T3/es not_active Expired - Lifetime
- 2001-11-05 EP EP01978757A patent/EP1339678B1/en not_active Expired - Lifetime
- 2001-11-05 EE EEP200300246A patent/EE200300246A/xx unknown
- 2001-11-05 CZ CZ20031257A patent/CZ20031257A3/cs unknown
- 2001-11-05 DK DK01978757T patent/DK1339678T3/da active
- 2001-11-05 IL IL15536801A patent/IL155368A0/xx unknown
- 2001-11-05 DE DE60130675T patent/DE60130675T2/de not_active Expired - Fee Related
- 2001-11-05 SI SI200130776T patent/SI1339678T1/sl unknown
- 2001-11-05 CN CNA018194877A patent/CN1476429A/zh active Pending
- 2001-11-05 JP JP2002544404A patent/JP3984164B2/ja not_active Expired - Lifetime
- 2001-11-05 EA EA200300379A patent/EA200300379A1/ru unknown
- 2001-11-05 CA CA002429850A patent/CA2429850C/en not_active Expired - Fee Related
- 2001-11-05 KR KR10-2003-7007109A patent/KR20030053063A/ko not_active Application Discontinuation
- 2001-11-05 MX MXPA03004623A patent/MXPA03004623A/es active IP Right Grant
- 2001-11-05 OA OA1200300141A patent/OA12533A/en unknown
- 2001-11-05 AT AT01978757T patent/ATE374182T1/de not_active IP Right Cessation
- 2001-11-05 PT PT01978757T patent/PT1339678E/pt unknown
- 2001-11-05 WO PCT/IB2001/002073 patent/WO2002042268A2/en active IP Right Grant
- 2001-11-05 PL PL01362030A patent/PL362030A1/xx not_active Application Discontinuation
- 2001-11-21 US US09/990,556 patent/US6552067B2/en not_active Expired - Fee Related
- 2001-11-23 UY UY27038A patent/UY27038A1/es not_active Application Discontinuation
- 2001-11-23 HN HN2001000266A patent/HN2001000266A/es unknown
- 2001-11-26 TN TNTNSN01166A patent/TNSN01166A1/fr unknown
- 2001-11-26 SV SV2001000746A patent/SV2003000746A/es unknown
- 2001-11-26 PE PE2001001180A patent/PE20020637A1/es not_active Application Discontinuation
- 2001-11-26 TW TW093115078A patent/TW200424170A/zh unknown
- 2001-11-26 AR ARP010105489A patent/AR035074A1/es unknown
- 2001-11-27 GT GT200100238A patent/GT200100238A/es unknown
- 2001-11-27 PA PA20018533901A patent/PA8533901A1/es unknown
- 2001-11-27 GT GT200100238AK patent/GT200100238AA/es unknown
-
2002
- 2002-12-20 US US10/326,366 patent/US6747054B2/en not_active Expired - Fee Related
-
2003
- 2003-04-03 BG BG107697A patent/BG107697A/xx unknown
- 2003-04-10 IS IS6775A patent/IS6775A/is unknown
- 2003-04-10 ZA ZA200302803A patent/ZA200302803B/en unknown
- 2003-05-13 MA MA27159A patent/MA26961A1/fr unknown
- 2003-05-26 NO NO20032360A patent/NO20032360L/no not_active Application Discontinuation
- 2003-05-27 EC EC2003004623A patent/ECSP034623A/es unknown
- 2003-09-23 US US10/668,633 patent/US7192979B2/en not_active Expired - Fee Related
-
2007
- 2007-05-11 JP JP2007127062A patent/JP2007197467A/ja active Pending
- 2007-11-06 CY CY20071101420T patent/CY1106976T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0400807A2 (hu) | EP4 receptor szelektív agonisták csontritkulás kezelésében | |
AP2001002357A0 (en) | EP4 receptor selective agonists in the treatment of osteoporosis. | |
HUP0402311A2 (hu) | Naftiridinszármazékok, eljárás előállításukra, és alkalmazásuk foszfodiészteráz izoenzim 4 (PDE4) gátló hatóanyagként és ezeket tartalmazó gyógyszerkészítmények | |
HUP0402492A2 (hu) | 5HT4 részleges agonistát tartalmazó gyógyszerkészítmények | |
MX9600618A (es) | Composicion dental y metodo. | |
HUP0400467A2 (hu) | 2-Iminopirrolidin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0104768A2 (hu) | 4-Amino-3-oxo-azepán proteáz inhibitorok és az ezeket tartalmazó gyógyszerkészítmények | |
HUP0401100A2 (hu) | Fogápoló készítmény | |
HUP0402463A2 (hu) | Pirazolo-piridin gyűrűt tartalmazó laktámok és származékaik, valamint az ezeket tartalmazó Xa faktor gátlására szolgáló gyógyszerkészítmények | |
IT1246342B (it) | Composizione adesiva per protesi dentarie e procedimento per la sua preparazione. | |
HUP0100669A2 (hu) | Szerin proteázokat gátló peptidszármazékok és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények | |
ATE486587T1 (de) | Formulierungen zur oralen verabreichung von wirkstoffen | |
HUP0302474A2 (hu) | Terápiásan hatásos tropánszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0400636A2 (hu) | Azetidinszármazékokat tartalmazó gyógyszerkészítmények, új azetidinszármazékok és előállításuk | |
HUP9701264A1 (hu) | Aminosavszármazékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
DK0477244T3 (da) | Indlægningsmateriale til udvidelse af tandkødslommen | |
CY1112139T1 (el) | Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης | |
IL160171A0 (en) | Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
HUP0003413A2 (hu) | Új kondenzált piridinszármazékok, eljárás előállításukra és az azokat tartalmazó gyógyászati készítmények | |
AR024748A1 (es) | Compuestos derivados de titanio, su preparacion y su utilizacion. | |
AU2003271811A8 (en) | Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same | |
PT701449E (pt) | Processo de preparacao de uma forma de dosagem solida oral contendo diclofenac | |
HUP0105308A2 (hu) | Eletriptán-hidrobromid-monohidrát, eljárás az előállítására és a vegyületet tartalmazó gyógyszerkészítmények | |
HUP0402602A2 (hu) | Eljárás echinokandin-származékok előállítására, ezek alkalmazása, ezeket tartalmazó gyógyszerkészítmények és intermedierek | |
HUP0104804A2 (hu) | Tetrahidro-naftiridinil-származék, mint vitronektin receptor antagonista, eljárás előállítására és ezt tartalmazó gyógyszerkészítmény |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |